Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-
class science and the pursuit of R&D excellence drive Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases.
Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets.
Headquartered in Wilmington, Delaware, Incyte Corporation has operations in Switzerland and eight other European countries. For more information, visit www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte.